Osteoarthritis: New Insights
Authors: David D. Waddell
Journal: Annals of Internal Medicine (2002)

Letters1 January 2002Osteoarthritis: New InsightsDavid D. Waddell, MDDavid D. Waddell, MDLouisiana State University, Shreveport, LA 71103Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-1-200201010-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The authors of the review series on osteoarthritis (1) are to be commended for their effort to focus attention on advances in treatment and for their well-referenced, concise summary. Primary care providers need to become familiar with all options in order to offer comprehensive treatment programs. The omission of viscosupplementation, therefore, was surprising. The U.S. Food and Drug Administration approved hyaluronan-based viscosupplements in 1997 for the treatment of symptoms of knee osteoarthritis after failure of nonpharmacologic therapy and acetaminophen. Viscosupplements have been used clinically for osteoarthritis in Europe and Japan for over 10 years, and a high-molecular-weight ...References1. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, et al . Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med. 2000;133:726-37. [PMID: 11074906] LinkGoogle Scholar2. Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, et al . The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995;3:213-25. [PMID: 8689457] CrossrefMedlineGoogle Scholar3. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998;20:410-23. [PMID: 9663358] CrossrefMedlineGoogle Scholar4. Weiss C, Waddell D, Miller E. The availability of highly elastoviscous hylan for viscosupplementation can delay knee replacement in patients with advanced osteoarthritis. In: Kennedy JF, Phillips GO, Williams PA, Hascall VC, eds. Hyaluronan 2000. Cambridge: Woodhead; [In press]. Google Scholar5. Wobig M, Beks P, Dickhut A, Maier R, Vetter G. Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee. J Clin Rheumatol. 1999;5 Suppl 6 S24-S31. Google Scholar Author, Article, and Disclosure InformationAuthors: David D. Waddell, MDAffiliations: Louisiana State University, Shreveport, LA 71103 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOsteoarthritis: New Insights. Part 2: Treatment Approaches Conference Chair: David T. Felson , Conference Organizer: Reva C. Lawrence , Discussants: Marc C. Hochberg , Timothy McAlindon , Paul A. Dieppe , Marian A. Minor , Steven N. Blair , Brian M. Berman , James F. Fries , Morris Weinberger , Kate R. Lorig , Joshua J. Jacobs , and Victor Goldberg Osteoarthritis: New Insights Paul J. Rosch Osteoarthritis: New Insights Robert H. Palmer Osteoarthritis: New Insights David T. Felson and Timothy McAlindon Osteoarthritis: New Insights Thomas E. Lindow Metrics 1 January 2002Volume 136, Issue 1Page: 86KeywordsArthroscopyClinical trialsDrugsFood and Drug AdministrationKneesNSAIDsOrthopedicsOsteoarthritis ePublished: 1 January 2002 Issue Published: 1 January 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...